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Objective. Systemic lupus erythematosus is a mul-
tifactorial disease with a strong genetic component.
Previous studies have shown that a 129-derived chro-
mosome 1 interval (Sle16) on the C57BL/6 (B6) back-
ground is sufficient to induce humoral autoimmunity.
The aim of the present study was to elucidate the
mechanisms by which this locus contributes to the loss
of peripheral tolerance.
Methods. Anti–single-stranded DNA (anti-ssDNA)–
knockin transgenic mice (VH3H9R/V8R and VH3H9R)
were crossed with a B6 congenic line named B6.129chr1b
that carries the Sle16 locus. A parallel study of a gene-
targeted animal, whose mutated gene is located within
the 129chr1b interval on chromosome 1, was also per-
formed.
Results. The combination of VH3H9R/V8R with
the 129chr1b interval resulted in impaired B cell anergy,
and transgenic IgM and IgG anti-ssDNA antibodies
were found in the circulation. The presence of IgG2a
a
anti-ssDNA and IgM
a anti-Sm antibodies in sera indi-
cated that the autoreactive transgenic B cells underwent
class switching and epitope spreading. The 129chr1b
locus appeared to have a dominant effect, since trans-
genic antibodies were also detected in mice carrying a
single allele. The gene-targeted animals showed a simi-
lar phenotype.
Conclusion. The presence of a single 129chr1b
locus on the B6 background impaired B cell anergy,
prevented deletion of anti-DNA transgenic B cells, and
induced receptor revision. The findings of this study
also emphasize that the autoimmune phenotype ob-
served in mice with targeted genes located on chromo-
some 1 may simply arise from epistatic interactions
between the 129 and B6 parental strains.
Systemic lupus erythematosus (SLE) is an auto-
immune disease that displays highly variable clinical
features. The serologic hallmark of SLE is the produc-
tion of autoantibodies directed against a wide spectrum
of self antigens, especially nuclear components, such as
DNA. Several lines of evidence indicate that both in
humans and in animal models, SLE susceptibility is
inherited as a multifactorial genetic trait (1). To identify
the genetic components of SLE, linkage analyses have
been performed in spontaneous lupus–prone mice, and
these studies have led to the identification of several
genomic intervals (2). Interestingly, a great proportion
of the intervals detected are strain-specific, confirming
the genetic complexity of the disease and indicating the
presence of extensive heterogeneity in the genes that
contribute to the pathogenesis of SLE.
However, 1 interval, located on the distal region
of chromosome 1 in the mouse and on its orthologous
region in humans, has shown strong linkage in several
human and murine studies (3,4). One of the best char-
acterized loci in this region is Sle1b, which was identified
via linkage analysis of the lupus-prone NZM2410 mouse
model (5). This locus, when expressed on the C57BL/6
genetic background (B6.Sle1b), can induce a relatively
benign autoimmune disease characterized by loss of
tolerance to nuclear antigens, an increase in the propor-
tion of activated T cells and B cells, and mild spleno-
megaly. These features seem to be linked to a specific
haplotype of the signaling lymphocytic activation mole-
cule (SLAM)/CD2 family of genes, indicating that these
genes might mediate the autoimmune phenotype asso-
ciated with the Sle1b locus (6,7). However, in the same
chromosome 1 region, there are several other candidate
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2131genes, such as Apcs, Fcgr2, Cd55, Pdcd1, and Ro antigen.
All of these genes were inactivated in 129-derived
embryonic stem cells, and the knockout models dis-
played a variable degree of autoimmunity (8–12). How-
ever, the interpretation of the autoimmune phenotype
(13) observed in these gene-targeted models has recently
been questioned (14).
Studies by our group and others (8,15–17) have
shown that hybrid strains between 129 and C57BL/6
(B6) mice, commonly used in the generation of gene-
targeted mice, are spontaneously predisposed to the
development of humoral autoimmunity, with low levels
of renal disease. Genome-wide linkage studies con-
ducted on the 129  B6 hybrid mice identified a strong
association between a 129-derived segment on chromo-
some 1, now named Sle16, and the expression of auto-
antibodies (14,18). The autoimmune effect of this locus
has recently been defined further by the study of B6
subcongenic strains carrying 129 fragments of different
lengths (14,19). The analysis of these lines revealed that
a 129 interval between 87.9 cM and 100 cM (D1Mit15
and D1Mit115) was sufficient to induce the autoimmune
phenotype, and the congenic line carrying this fragment,
named B6.129chr1b, was selected for the present study.
It is noteworthy that the B6.129chr1b congenic mice
mirror the combination of genes created when a gene in
this region is targeted on 129 embryonic stem cells and
then backcrossed onto the B6 genetic background.
Immunoglobulin-transgenic models have been in-
strumental in understanding B cell regulation, revealing
several key mechanisms including receptor editing, de-
letion, anergy, and ignorance (20–24). Chen et al (25)
generated an anti-DNA–knockin model in which the
rearranged variable heavy chain (VH) gene of an anti-
DNA antibody (VH3H9) was inserted at the Igh locus.
This allowed the transgenic locus to undergo normal
editing, isotype switching, and somatic mutation. A
variety of light chains can combine with the VH3H9 to
yield anti-DNA antibodies (26), but only a few light
chains are able to “silence” VH3H9 so that it no longer
binds to DNA. By virtue of this characteristic, the mice
expressing only the VH3H9 chain (VH3H9R mice) can
generate anti-DNA specificities. When the VH3H9R
mice were crossed with the knockin transgenic light
chain V8 mice (27), the antibody generated in the
double-transgenic mice (VH3H9R/V8R mice) (28)
bound only single-stranded DNA (ssDNA) and not
double-stranded DNA (dsDNA) (27). Previous studies
with the VH3H9R mice showed that autoreactive trans-
genic B cells accumulated in the splenic marginal zone
and were regulated by anergy in the presence of a
nonautoimmune background, such as BALB/c (25,29)
and B6 (30,31), but were activated in a model of chronic
graft-versus-host disease (30). Similarly, the VH3H9R/
V8R-knockin transgenic B cells were regulated by
anergy in nonautoimmune disease–prone BALB/c mice,
while in autoimmune disease–prone MRL/Mp.lpr/lpr ani-
mals, transgenic B cells escaped tolerance induction and
underwent class switching and affinity maturation (32).
To determine whether the Sle16 locus could
influence the selection of self-reactive B cells, we bred
the B6.129chr1b mice with the VH3H9R.B6 mice and
the VH3H9R/V8R.B6 mice and monitored the regula-
tion and activation of anti-DNA–transgenic B cells
over a period of 10 months. A similar analysis was also
performed with mice deficient in serum amyloid P
component (B6. Apcs
/), chosen as an example of an
autoimmune mouse strain with a targeted deletion of
1 of the candidate genes located within the 129chr1b
region. The analysis of these mice showed that hemi-
zygosity of the Sle16 locus was sufficient to impair B cell
anergy and to induce class switching and epitope
spreading. The immunologic alterations were more pro-
nounced in mice that were homozygous for the Sle16
locus and were similar in the B6. Apcs
/ mice, indicat-
ing that the lack of serum amyloid P component had no
additional effect on the loss of B cell tolerance.
MATERIALS AND METHODS
Mice. C57BL/6 mice were obtained from Harlan Olac
(Bichester, UK). B6. Apcs
/ and B6.129chr1b mice (acknowl-
edged name B6.129-Sle16) were generated as previously de-
scribed (19,33). VH3H9R/V8R.B6 mice (25,27) were kindly
provided by Prof. M. Weigert (Gwen Knapp Center for Lupus
and Immunology Research, University of Chicago, Chicago,
IL). In order to generate the different cohorts of mice for
study, VH3H9R/V8R.B6 mice were crossed with B6. Apcs
/
mice, and the resulting VH3H9R/V8R.B6. Apcs
/– mice were
then crossed with B6. Apcs
/ mice to obtain VH3H9R/
V8R.B6. Apcs
/ animals. Likewise, VH3H9R/V8R.B6
mice were crossed with B6.129chr1b mice, and the resulting
VH3H9R/V8R.B6129.chr1b
129/B6 mice were then crossed
with B6.129chr1b mice to obtain VH3H9R/V8R.B6129.
chr1b
129/129 animals. Only female animals were studied. Mice
were bled at regular intervals starting from the age of 2 months
and were killed at 10 months of age.
The mice were genotyped by polymerase chain reac-
tion (PCR) analysis, using primers specific for each allele.
PCR primers were as follows: for Apcs genotyping, Sap5/9
(5-ATTGATTTCCCAGCACAGGGG-3), Sap8/ (5-GAT-
CAGTTTCAGATTCTCTGG-3), and neo (5-GGGGATC-
GGCAATAAAAAGAC-3); for VH3H9R genotyping,
MW114 (5-CTGTCAGGAACTGCAGGTAAGG-3) and
MW162 (5-CATAACATAGGAATATTTACTCCTCGC-3)
(29); for V8R genotyping, MW133 (5-GGTACCTGTGGG-
GACATTGTG-3) and MW157 (5-AGCACCGAACGTGA-
GAGG-3) (34); and for 129chr1b genotyping, D1Mit15 and
D1Mit115 (19).
2132 FOSSATI-JIMACK ET ALAnimals were maintained under specific pathogen-free
conditions. All animal care and procedures were conducted
according to institutional guidelines and were approved by the
local ethics committee.
Immunofluorescence staining. Flow cytometry was
performed using 4-color staining of cells, and the results were
analyzed with a FACSCalibur instrument (Becton Dickinson,
Mountain View, CA). The following antibodies were used:
anti-B220 (clone RA3-6B2), anti-CD4 (clone GK1.5), anti-
CD5 (clone 53-7.3), anti-CD11b (clone M1-70), anti-CD19 (clone
1D3), anti-CD23 (clone B3B4), anti-CD21/CD35 (clone 7G6),
anti-CD25 (clone PC61), anti-CD69 (clone H1.2F3), anti-CD90.2
(clone 53-2.1), anti-CD138 (clone 281-2), anti-IgM
a (clone DS-1).
All antibodies were purchased from BD PharMingen (San Diego,
CA), with the exception of the anti-VH3H9 idiotype (clone
1.209), which was a kind gift from Prof. M. Weigert (35).
Biotinylated antibodies were detected using an allophyco-
cyanin-conjugated streptavidin antibody (BD PharMingen).
Staining was performed in the presence of a saturating concen-
tration of 2.4G2 monoclonal antibody (anti-FcRII/III). Data
were analyzed using WinMDI software (version 2.8; Scripps
Institute and Research Foundation, La Jolla, CA).
Spleens were snap-frozen, sectioned, and fixed in
acetone. Sections were stained with fluorescein isothiocyanate
(FITC)–conjugated anti-CD90.2, FITC-conjugated peanut
agglutinin (PNA) (both from Vector, Peterborough, UK), and
biotin-conjugated anti-VH3H9 idiotype antibody 1.209, fol-
lowed with streptavidin–phycoerythrin (BD PharMingen).
Serologic analyses. Anti-ssDNA, antihistone, anti-
chromatin, and anti-Sm antibodies were measured by enzyme-
linked immunosorbent assay (ELISA) as described previously
(36). Briefly, the different antigens (DNA from Sigma-Aldrich,
Dorset, UK; histone from Roche Diagnostics, Lewes, UK;
chromatin from Lorne Laboratories, Reading, UK; and Sm
from ImmunoVision, Springdale, AR) were coated onto mi-
crotiter plates. Serum samples were diluted appropriately.
Bound antibodies were detected with biotinylated mouse anti-
mouse IgM
a (clone DS-1) and mouse anti-mouse IgG2a
a
(clone 8.3), followed by a streptavidin–alkaline phosphatase
conjugate (all from BD PharMingen). All autoantibody results
are expressed in arbitrary ELISA units, as determined by
reference to a standard curve derived from serum pools
containing high titers of autoantibodies. For total IgM
a and
IgG2a
a determinations, precipitated serum immunoglobulins
were coated directly on the microtiter plates and detected as
described above.
Renal assessment. Proteinuria was assessed using
Haema-Combistix (Bayer Diagnostics, Newbury, UK). Kid-
neys were fixed in Bouin’s solution and embedded in paraffin,
and sections were stained with periodic acid–Schiff reagent.
Glomerular histologic features were scored in a blinded man-
ner, using a scale of 0–4 (where 0  normal and 4  severe
proliferative glomerulonephritis in 90% of glomeruli), as
previously described (19). FITC-conjugated goat antibody
against mouse total IgG (Sigma-Aldrich) and against mouse
C3 (ICN Pharmaceuticals, Costa Mesa, CA) were used to stain
snap-frozen sections. Staining with FITC-conjugated anti-
bodies was quantified as previously described (37) and ex-
pressed as arbitrary fluorescence units.
Statistical analysis. The data are presented as the
median and range, except where indicated otherwise. The
nonparametric Mann-Whitney U test was applied throughout.
P values less than 0.05 were considered significant. For the
findings of the FACS analysis, we applied the analysis of
variance Kruskal-Wallis test, followed by Dunn’s multiple com-
Figure 1. IgM
a anti–single-stranded DNA (anti-ssDNA) at 10 months
of age in B6 (F), B6.129chr1b
129/129 (}), B6.129chr1b
129/B6 (Œ), and
B6. Apcs
/ (E) mice carrying A, the VH3H9R/VL8R transgene or B,
the VH3H9R transgene. Each symbol represents 1 mouse; bars show
the median arbitrary enzyme-linked immunosorbent assay units
(AEU). Levels of total IgM
a were similar in the VH3H9R/VL8R
cohorts (median AEU 43 [range 21–112] in VH3H9R/VL8R.B6, 40
[range 16–120] in VH3H9R/VL8R.B6.129chr1b
129/129, 34 [range 3–65]
in VH3H9R/VL8R.B6.129chr1b
129/B6, and 50 [range 12–160] in
VH3H9R/VL8R.B6. Apcs
/ mice) and in the VH3H9R cohorts
(median AEU 67 [range 47–110] in VH3H9R.B6, 83 [range 44–102] in
VH3H9R.B6.129chr1b
129/129, 60 [range 20–138] in VH3H9R.B6.
129chr1b
129/B6, and 74 [range 40–155] in VH3H9R.B6. Apcs
/ mice). P
values were determined by Mann-Whitney U test.
B CELL TOLERANCE IN 129chr1b CONGENIC MICE 2133parison test. Statistics were calculated using GraphPad Prism
software, version 3.0 (GraphPad Software, San Diego, CA).
RESULTS
Defective B cell tolerance. B6.129chr1b and
B6. Apcs
/mice have been reported to develop a
lupus-like disease (8,19). To determine the mechanisms
underlying the loss of tolerance in these mice, the
anti–DNA VH3H9R/VL8R–transgenic alleles were trans-
ferred to these mice by breeding. VH3H9R/VL8R.B6.
129chr1b
129/B6 mice carrying only 1 copy of the 129chr1b
allele were also analyzed. The expression of the anti-DNA–
transgenic allele was assessed by measuring the transgenic-
specific immunoglobulin allotype IgH
a, since the allotype
of endogenous B6 immunoglobulins is IgH
b (Figure 1A).
As expected, no IgM
a anti-ssDNA antibodies were found
in the serum of VH3H9R/VL8R.B6 mice. In contrast, the
majority of the VH3H9R/VL8R.B6.129chr1b
129/129 and
VH3H9R/VL8R.B6. Apcs
/mice produced significant
amounts of transgenic anti-ssDNA antibodies. As a result
of the gene-targeting technique, B6. Apcs
/ mice carry a
129 fragment (168.7–179.4 Mb) of a length similar to that
in B6.129chr1b mice (168.7–182.3 Mb). No statistical dif-
ference was observed between these 2 groups of mice,
indicating that the lack of serum amyloid P component did
not contribute to the breakage of B cell tolerance.
Of note, 40% of the VH3H9R/VL8R.B6.129chr1b
129/B6
mice also secreted IgM
a anti-ssDNA antibodies, which
suggests that hemizygosity in the 129chr1b region was itself
sufficient to break tolerance, although to a lesser extent.
The same analysis was performed in the
VH3H9R animals. In this model, the 3H9 heavy chain
can freely combine with endogenous light chains, giving
rise to a limited repertoire of autoantibodies. As previ-
ously reported (31), negligible levels of anti-ssDNA
antibodies were detected in the sera of VH3H9R.B6
mice (Figure 1B). However, the presence of the
129chr1b locus, even as a single allele, induced signifi-
cant levels of IgM
a anti-ssDNA antibodies. The effect
of the 129chr1b locus was more marked in the homo-
zygous VH3H9R.B6.129chr1b
129/129 mice than in the
VH3H9R.B6.129chr1b
129/B6 animals, while the absence
of serum amyloid P component had no additional effect.
A similar pattern was observed when we measured IgM
a
antihistone antibodies (data not shown).
Isotype switching of the transgenic antibodies.
The VH3H9R/V8R-knockin model allows the trans-
genic locus to undergo isotype switching, and we were
therefore able to measure IgG2a
a anti-ssDNA anti-
bodies. Consistent with the results obtained with the
IgM
a autoantibodies, markedly increased amounts of
IgG2a
aanti-ssDNAantibodieswerefoundintheVH3H9R/
VL8R.B6.129chr1b
129/129,V H3H9R/VL8R.B6. Apcs
/,
and VH3H9R/VL8R.B6.129chr1b
129/B6 mice as com-
pared with the VH3H9R/VL8R.B6 controls (Figure
2A). Again, there was no statistical difference be-
Figure 2. IgG2a
a anti–single-stranded DNA (anti-ssDNA) at 10 months
of age in B6 (F), B6.129chr1b
129/129 (}), B6.129chr1b
129/B6 (Œ), and
B6. Apcs
/ (E) carrying A, the VH3H9R/VL8R transgene or B, the
VH3H9R transgene. Each symbol represents 1 mouse; bars show the
median arbitrary enzyme-linked immunosorbent assay units (AEU).
Levels of total IgG2a
a were similar in the VH3H9R/VL8R cohorts
(median AEU 7.8 [range 7.3–9.2] in VH3H9R/VL8R.B6, 7.9 [range
5.8–9.3] in VH3H9R/VL8R.B6.129chr1b
129/129, 7.5 [range 6.6–8.4] in
VH3H9R/VL8R.B6.129chr1b
129/B6, and 7.5 [range 5.8–9.5] in VH3H9R/
VL8R.B6. Apcs
/ mice) and in the VH3H9R cohorts (mean AEU 7.9
[range 4.7–9.1] in the VH3H9R.B6, 8.0 [range 7.3–9.0] in
VH3H9R.B6.129chr1b
129/129, 7.5 [range 4.5–9.0] in VH3H9R.B6.
129chr1b
129/B6, and 7.9 [range 6.9–8.3] in VH3H9R.B6. Apcs
/ mice). P
values were determined by Mann-Whitney U test.
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genic mice and the serum amyloid P component–
deficient animals. Of note, in this assay, the VH3H9R/
VL8R.B6.129chr1b
129/B6 mice had levels of IgG2a
a
anti-ssDNA antibodies that were similar to those de-
tected in the VH3H9R/VL8R.B6.129chr1b
129/129 mice.
Similar findings were observed in the VH3H9R
transgenic mice, with significant levels of IgG2a
a anti-
ssDNA antibodies in all groups carrying the 129chr1b locus
(VH3H9R.B6.129chr1b
129/129,V H3H9R.B6.129chr1b
129/B6,
and VH3H9R.B6. Apcs
/) (Figure 2B). IgG2a
a anti-
histone antibodies were found in 4 of 13 VH3H9R.B6.
129chr1b
129/129 mice and in 4 of 9 VH3H9R.B6. Apcs
/
mice, but only in 1 of 17 VH3H9R.B6.129chr1b
129/B6 mice
(data not shown). None of the 7 VH3H9R.B6 mice had
circulating IgG2a
a antihistone antibodies.
EpitopespreadingoftransgenicBcells.VH3H9R/
V8R mice can generate only antibodies against ssDNA.
However, previous studies of VH3H9R/VL8R.MRL.
lpr/lpr mice have shown that when tolerance is broken,
VH3H9R/VL8R-transgenic B cells can undergo recep-
tor editing in order to change the specificity of the
transgenic B cells toward other autoantigens (32). In
light of these previous observations, we measured
IgM
a autoantibodies against different nuclear antigens
at different time points in the VH3H9R/VL8R.B6 co-
horts (Figure 3). At an early stage of the disease (age 2
months) in mice carrying the 129chr1b locus, IgM
a
autoantibodies were mainly directed against ssDNA.
However, at later time points (ages 5 months and 10
months), IgM
a against other autoantigens (Sm and
chromatin) were detectable, indicating an expansion of
the autoantibody repertoire.
Findings of the renal assessment. At 10 months
of age, all mice were killed, and their kidneys were
harvested and processed for examination by light mi-
croscopy (Table 1). Renal sections stained with periodic
acid–Schiff were graded in a blinded manner using a
scale of 0–4 (19). As expected, neither VH3H9R/VL8R.
B6-transgenic nor VH3H9R.B6-transgenic mice had sig-
nificant signs of renal disease. Interestingly, none of the
transgenic mice carrying the 129chr1b fragment devel-
oped severe glomerulonephritis, despite having signifi-
cant titers of autoantibodies in their circulation. Of note,
even in the transgenic mice lacking serum amyloid P
component, which has been implicated in end-organ
injury, there was no histologic evidence of severe renal
damage.
We also investigated whether the high levels of
circulating autoantibodies were associated with an in-
creased deposition of immune complexes in the kidneys
(Table 1). Fluorescence quantification of glomerular
IgG deposition revealed a significantly higher amount in
VH3H9R.B6.129chr1b
129/129 and VH3H9R.B6. Apcs
/
mice than in VH3H9R.B6 mice (P  0.0006 and P 
0.0121, respectively). Similarly, VH3H9R/VL8R.B6.
129chr1b
129/129 and VH3H9R/VL8R.B6. Apcs
/ mice
had more IgG deposited in their kidneys than did the
Figure 3. IgM
a anti–single-stranded DNA (anti-ssDNA), antihistone,
antichromatin, and anti-Sm autoantibodies (autoAb) in VH3H9R/
VL8R.B6, VH3H9R/VL8R.B6.129chr1b
129/129,V H3H9R/
VL8R.B6.129chr1b
129/B6, and VH3H9R/VL8R.B6. Apcs
/ mice at
ages A, 2 months, B, 5 months, and C, 10 months. Values are the mean
and SEM arbitrary enzyme-linked immunosorbent assay units (AEU).
B CELL TOLERANCE IN 129chr1b CONGENIC MICE 2135VH3H9R/VL8R.B6 controls (P  0.0513 and P 
0.0140, respectively). Despite the high levels of IgG in
their kidneys, the levels of glomerular C3 deposition
were similar among the cohorts (for VH3H9R.B6.
129chr1b
129/129 and VH3H9R.B6. Apcs
/ versus
VH3H9R.B6, P  0.6200 and P  0.0727, respectively;
for VH3H9R/VL8R.B6.129chr1b
129/129 and VH3H9R/
VL8R.B6. Apcs
/ mice versus VH3H9R/VL8R.B6,
P  0.7308 and P  0.8182, respectively).
Findings of flow cytometric analysis of splenic B
cells. In order to determine if the serologic data were
accompanied by phenotype changes in T and B lympho-
cytes, we performed a comprehensive analysis of the
splenic subpopulations (Table 2). The proportion of cells
expressing the transgenic alleles was first determined by
assessing the allotype of their B cell receptor (surface
IgM). The great majority of the VH3H9R/VL8R.B6 B
cells (80%) were IgM
a-positive, indicating that almost
all B cells had used the rearranged transgenic alleles.
The presence of the 129chr1b locus did not affect the
proportion of transgenic-positive B cells or the level of
surface IgM expression (data not shown). The different
subpopulations of B cells were then examined. Apart
from a significant decrease in marginal zone B cells in
VH3H9R/VL8R.B6.129chr1b
129/129,V H3H9R/VL8R.B6.
129chr1b
129/B6, and VH3H9R/VL8R.B6. Apcs
/ mice as
compared with the VH3H9R/VL8R.B6 mice (Table 2),
no other consistent differences were observed between
these 4 experimental cohorts.
Similarly, in the VH3H9R.B6 mice, nearly every
B cell was IgM
a-positive, and the presence of the
129chr1b allele had no effect on the proportion of B
Table 1. Assessment of renal disease in the different mouse strains*
Mouse strain GN score IgG, AFU C3, AFU
VH3H9R/VL8R.B6 0.0 (0.0–2.0) 18.3 (13.0–29.0) 35.9 (28.2–40.2)
.129chr1b
129/129 0.0 (0.0–1.0) 24.6 (20.8–27.6)† 32.1 (21.4–40.7)
.129chr1b
129/B6 0.0 (0.0–2.0) ND ND
.Apcs
/ 0.0 (0.0–1.0) 30.7 (20.0–38.3)† 31.7 (28.4–47.1)
VH3H9R.B6 0.0 (0.0–1.0) 19.1 (9.9–26.0) 26.7 (20.4–35.6)
.129chr1b
129/129 0.0 (0.0–1.0) 36.0 (25.2–58.8)‡ 27.8 (19.5–45.4)
.129chr1b
129/B6 1.0 (0.0–1.0) ND ND
.Apcs
/ 0.0 (0.0–2.0) 27.4 (25.8–35.8)‡ 40.0 (27.0–50.5)
* Glomerulonephritis (GN) was graded on a scale of 0–4 as described elsewhere (19). Deposition of IgG
and C3 in renal glomeruli was expressed in arbitrary fluorescence units (AFU). In 10-month-old B6 mice
(negative controls), the median levels were 19.7 AFU (range 13.6–27.3) for IgG and 32.3 AFU (range
22.8–40.1) for C3, and in nephritic 6-month-old (NZB  NZW)F1 mice (positive controls), the median
levels were 38.9 AFU (range 31.9–50.9) for IgG and 42.5 AFU (range 41.1–64.2) for C3. Values are the
median (range) in 4–7 mice per group. ND  not done.
† P  0.05 versus VH3H9R/VL8R.B6 mice, by Mann-Whitney U test.
‡ P  0.05 versus VH3H9R.B6 mice, by Mann-Whitney U test.
Table 2. Splenic cell populations in the different mouse strains at 10 months of age*
Mouse strain
No. of
cells
(10
6)
Cell type (staining/gate)
%
transgenic
B cells
(IgM
a/B220)
%
T1 B cells,
(CD21/35,
CD23/
CD19)
Marginal zone B
cells (CD21/35
high,
CD23
low/CD19)
Follicular zone B
cells (CD21/35,
CD23
high/CD19) %
plasmacytes
(CD138/
CD90.2,
CD19)
%
activated
T cells
(CD69/
CD4)
%
regulatory
T cells
(CD25
high/
CD4) %
No. of
cells
(10
5) %
No. of
cells
(10
5)
VH3H9R/VL8R.B6 319  60 83.8  2.8 14.3  4.2 11.7  13 7  10 63.8  2.9 195  34 4.3  0.4 26.2  3.9 8.0  1.1
.129chr1b
129/129 153  53 84.7  2.0 13.0  6.4 5.2  0.4† 17  9 77.3  3.1 142  52 4.4  0.6 22.1  6.2 5.2  1.3
.129chr1b
129/B6 258  122 80.8  4.7 16.7  8.6 5.9  0.8† 8  3 71.4  4.1 102  37 4.0  0.8 16.1  1.5 5.3  1.1
.Apcs
/ 371  55 89.2  1.1 13.2  7.6 7.0  1.2† 29  5 69.5  4.0 308  43 5.3  0.6 28.7  2.9 7.3  1.2
VH3H9R.B6 245  49 87.4  1.9 14.2  4.9 25.3  2.0 62  9 48.2  3.4 116  19 5.1  0.8 25.8  2.6 7.3  0.7
.129chr1b
129/129 186  39 81.7  5.0 18.0  5.1 22.1  2.0 42  12 49.1  2.2 88  22 5.7  0.6 26.7  3.4 5.4  0.6
.129chr1b
129/B6 121  29 79.4  4.0 21.3  4.9 23.9  1.6 25  7 44.3  2.8 45  11 4.5  0.8 26.9  3.5 5.8  0.8
.Apcs
/ 388  51 89.1  1.5 13.2  3.5 21.7  4.2 75  14 46.0  4.8 164  23 6.3  1.2 41.5  1.4 6.8  0.9
* Values are the mean  SEM of at least 7 mice per group. Percentages refer to the percentage of cells stained within the gated population.
† P  0.05 versus VH3H9R/VL8R.B6 mice, by Kruskal-Wallis test.
2136 FOSSATI-JIMACK ET ALcells expressing the transgenic allele. Consistent with
the findings in mice of other genetic backgrounds (38),
the VH3H9R.B6 mice had more marginal zone B cells
compared with the VH3H9R/VL8R.B6 mice (mean 
SEM 25.3  2.0 versus 11.7  1; P  0.0003). How-
ever, despite high titers of transgenic autoantibodies,
VH3H9R.B6.129chr1b
129/129,V H3H9R.B6.129chr1b
129/B6,
and VH3H9R.B6. Apcs
/ mice displayed a marginal
zone of similar size as that of the VH3H9R.B6 mice.
No substantial differences in the percentages of acti-
vated T cells or regulatory T cells were observed in the
transgenic animals.
We also explored whether the loss of tolerance
was accompanied by alterations of the splenic architec-
ture (39). As previously described in VH3H9R.B6 and
VH3H9R/VL8R.B6 mice, idiotype-positive B cells re-
mained at the border of the T cell zone (Figure 4A) (30).
However, in the VH3H9R.B6.129chr1b
129/129,V H3H9R/
VL8R.B6.129chr1b
129/129,V H3H9R.B6. Apcs
/, and
VH3H9R/VL8R.B6. Apcs
/ mice, some idiotype-
positive B cells were found inside the T cell zone (Figure
4B). In addition, very few germinal centers were present
in spleens from the VH3H9R.B6 mice (median of 2
germinal centers per section [range 1–2]) and the
VH3H9R/VL8R.B6 mice (median of 1 germinal center
per section [range 0–5]), and they did not have a ring of
idiotype-positive B cells (Figure 4C). Instead, in the
spleens of VH3H9R.B6.129chr1b
129/129 (median of 3
germinal centers per section [range 0–5]), VH3H9R/
VL8R.B6.129chr1b
129/129 (median of 7 germinal centers
per section [range 3–11]), VH3H9R.B6. Apcs
/ (me-
dian of 9 germinal centers per section [range 2–12]), and
VH3H9R/VL8R.B6. Apcs
/ (median of 8 germinal
centers per section [range 4–20]) mice, germinal centers
were easily detectable (P  0.05) and idiotype-positive
B cells surrounded the PNA core (Figure 4D).
DISCUSSION
Multiple genetic loci are known to contribute to
the development of SLE. Recently, it was shown that
epistatic interactions between 129 and B6 genes, even
Figure 4. Representative immunostaining of spleen sections from A and C, VH3H9R.B6 mice and
B and D, VH3H9R.B6.129chr1b
129/129 mice. Idiotype-positive B cells (red) localized at the border
of the T cell zone (green) in VH3H9R.B6 mice (A), whereas in VH3H9R.B6.129chr1b
129/129 mice,
they were found inside the T cell zone (B) (arrows). (Original magnification  40.) Peanut
agglutinin (PNA) staining (green) revealed very few germinal centers (arrowhead) in the spleens
of VH3H9R.B6 mice (C), whereas several PNA germinal centers (arrowheads) surrounded by
idiotype-positive B cells (red) were found in the VH3H9R.B6.129chr1b
129/129 mice (D). (Original
magnification  10.)
B CELL TOLERANCE IN 129chr1b CONGENIC MICE 2137though neither strain is lupus-prone, can lead to the
development of a spontaneous lupus-like disease (8,15–
17). Genetic linkage and congenic strain analyses have
confirmed that a 129-derived region on chromosome 1
(Sle16) is strongly linked to the production of high
titers of autoantibodies in the context of a B6 back-
ground. In order to elucidate the pathways that con-
tribute to this strain-specific epistasis, we turned to
well-established transgenic models of B cells expressing
anti-DNA antibodies, the VH3H9R/VL8R.B6- and
VH3H9R.B6-knockin models.
Several checkpoints present during B cell ontog-
eny avoid the production of self-reactive autoanti-
bodies. Centrally, most autoreactive specificities are
removed by deletion and editing before entering the
mature B cell compartment; however, some others are
regulated by anergy and exit to the periphery, where
they can be rescued (40). Serologic analysis of the
VH3H9R/VL8R.B6- and VH3H9R.B6-transgenic mice
showed that the presence of a single 129chr1b locus
impaired B cell anergy. The anergic B cells may have
been rescued by a strong cross-link of the B cell recep-
tor. In this context, one could speculate that the de-
fective uptake of apoptotic cells described in 129chr1b
mice (19) might provide a large source of aggregated
autoantigens and give a strong signal. In addition, pre-
liminary data suggest that B6.129chr1b B cells are more
susceptible to B cell receptor cross-linking.
Another time when autoreactive B cells may
arise is during germinal center reactions, when somatic
hypermutation occurs. At this checkpoint, B cell survival
and priming depend heavily on T cell help, indicating
that a considerable role in maintaining B cell tolerance
in the periphery is deferred to the T cells (41). Con-
trary to traditional immunoglobulin-transgenic models,
in the VH3H9R/VL8R.B6- and VH3H9R.B6-knockin
mice, the rearranged V genes are located upstream of
the constant region, allowing the transgenic B cells to
undergo isotype switching, editing, and somatic muta-
tion, processes that give us insight into the peripheral
tolerance in these mice. In both models, the presence of
the 129chr1b locus induced the transgenic B cells to
produce IgG2a
a anti-ssDNA, indicating that these cells
had entered the germinal center, where they received
T cell help in order to switch. Consistent with this,
immunostaining of spleen sections showed several ger-
minal centers with a ring of idiotype-positive B cells
and isolated idiotype-positive B cells in the T cell zone
only in mice carrying the 129chr1b locus. However, in
these lupus-prone mice, we did not observe clusters of
idiotype-positive B cells to suggest extrafollicular B cell
maturation (39).
One essential feature of germinal center reac-
tion is affinity maturation, in which antibodies under-
go somatic mutation in order to generate antibodies
with higher specificity or antibodies against different
antigenic specificities. Interestingly, transgenic IgM
a
antihistone, antichromatin, and anti-Sm were detected
at 10 months of age in the VH3H9R/VL8R.B6 mice
carrying the 129chr1b locus, indicating that the trans-
genic B cells had undergone somatic diversification
either by V-chain replacement or by somatic mutation.
This epitope spreading suggests an antigen-driven mat-
uration of the transgenic B cells, and again, inefficiently
cleared effete cells might have been the source of these
autoantigens (19).
B6.Sle1b mice, another well-characterized con-
genic strain carrying an NZM2410 fragment of chro-
mosome 1, has been shown to break anergy in the
sHEL–Ig
HEL model (42). The 129chr1b locus (between
168.7 Mbp and 182.3 Mbp) spans the same chromosome
1 interval encompassed by the Sle1b locus (between
171.8 Mbp and 173.1 Mbp) (7). Recent genomic char-
acterization of the Sle1b locus has identified a cluster of
SLAM/CD2 family genes as the strongest candidate
genes for mediating the Sle1b autoimmune phenotype
(6). Of note, the autoimmune-associated haplotype of
the B6.Sle1b mice, called SLAM/CD2 haplotype 2, is
also present in 129/SvJ mice (6), indicating that these 2
models may share some of the pathways that lead to loss
of peripheral tolerance. Reported data indicate that 1 of
the SLAM genes, Ly108, is associated with a defect in
immature B cells, leading possibly to an increase in T1 B
cells in the B6.Sle1b mouse spleens (42). Similarly, we
found a slight increase in the proportion of T1 B cells in
the nontransgenic 129chr1b congenic mice (data not
shown). However, in the anti-ssDNA–transgenic mice,
no consistent expansion of T1 B cells was observed at
the time point studied (10 months of age).
B cells that produce potentially pathogenic auto-
antibodies are thought to home to the marginal zone
(38,43), and sequestration to this site is believed to
prevent them from entering into the germinal center and
developing the properties of pathogenic B cells. Consis-
tent with this idea, in VH3H9R/VL8R.B6 mice carrying
the 129chr1b locus, we detected IgG2a
a autoantibodies
in the circulation and found that the proportion of
marginal zone B cells was markedly reduced compared
with that in VH3H9R/VL8R.B6 mice, suggesting that
the 129chr1b locus favored the entry of the autoreactive
transgenic B cells into the germinal center. In the single
heavy chain–transgenic mice (VH3H9R), the marginal
zone compartment was enlarged as compared with that
in the VH3H9R/VL8R.B6 and B6 mice (present study
2138 FOSSATI-JIMACK ET ALand ref. 38). Interestingly, this expansion was compara-
ble in all animals, including those that had broken
tolerance (VH3H9R.B6.129chr1b
129/129,V H3H9R.B6.
129chr1b
129/B6, and VH3H9R.B6. Apcs
/ mice), indi-
cating that this may reflect not only trapping of auto-
reactive B cells, but also some developmental blocking.
In this context, it is noteworthy that other single heavy
chain–transgenic models have displayed a similar pheno-
type (44,45).
The entry and survival of B cells through a
germinal center reaction depend on T cells. Surprisingly,
we failed to detect a significant increase in activated
T cells in our transgenic mice. However, we analyzed
only a limited number of T cell markers, and this may
account for our findings. Recent studies have increas-
ingly emphasized the importance of CD4,CD25 reg-
ulatory T cells in autoimmune disease. In particular, a
subset of regulatory T cells has been identified that
localizes to the germinal center and is able to inhibit the
production and survival of immunoglobulin as well as
activation-induced cytidine deaminase expression by
germinal center B cells (46). Moreover, regulatory T cell
activity has been shown to be important for preventing
DNA-specific autoantibody production that is induced
by T helper cells (40). We previously reported a signif-
icant decrease in the number of CD4,CD25 regula-
tory T cells in 12-month-old B6.129chr1b mice (19). In
the anti-DNA–transgenic 129chr1b mice, we observed a
tendency toward fewer regulatory T cells, but this did
not reach statistical significance. On the other hand, we
have also shown that in B6.129chr1b mice, the CD4,
CD25– T cells were resistant to suppression by regula-
tory T cells, which suggests a potential new mechanism
for the loss of peripheral tolerance in this lupus strain
(47).
Taken together, our data suggest that genes
within the 129chr1b locus break B cell tolerance, induce
T cells to provide help to B cells undergoing a germinal
center reaction, and increase the availability of auto-
antigens. Interestingly, 1 copy of the 129chr1b locus was
sufficient to induce all these effects, although to a lesser
degree than that produced by 2 129chr1b alleles. One of
the candidate genes within the Sle16 locus is Apcs, which
is supported by the observation that B6. Apcs
/ mice
developed a lupus-like illness with autoantibody pro-
duction and nephritis. However, these mice carry a 129
fragment that is equivalent to the one present in
129chr1b mice. In our study, anti-DNA–transgenic
Apcs
/ B cells had impaired induction of anergy similar
to that in the transgenic 129chr1b B cells, which further
supports the view that this gene is neither the primary
initiator of loss of tolerance nor a modifier of humoral
autoimmunity.
B6. Apcs
/ mice, in contrast to B6.129chr1b
mice, have been shown to develop renal inflammation,
suggesting that this gene may play a protective role in
lupus nephritis (8,19). However, neither VH3H9R/
VL8R.B6. Apcs
/ nor VH3H9R.B6. Apcs
/ mice de-
veloped kidney disease, despite having high levels of
autoantibodies. This may reflect the fact that transgenic
autoantibodies are of low affinity and, despite being
present in the kidneys, are unable to activate comple-
ment and induce tissue damage.
Another candidate gene located within the
129chr1b locus is Fcgr2b. Several studies have linked this
gene to SLE (48,49), and Fcgr2b-deficient mice have
been shown to develop a lupus-like illness (9). These
mice crossed with the VH3H9R.B6 mice failed to break
B cell tolerance; however, when they were bred with
another anti-DNA–transgenic model (VH3H9-56R.B6),
they displayed a marked increase in levels of IgG
anti-DNA (31). Taken together, these observations
would suggest that that the Fcgr2b gene may act as a
weak modifier of disease (31).
In conclusion, genes located within the 129chr1b
locus on a B6 genetic background were able to rescue
anergic B cells and to induce class switching and recep-
tor revision, whereas the lack of serum amyloid P
component had no additional effect. The immunologic
alterations were present even in hemizygotes, indicating
that the Sle16 locus plays a key role in autoimmunity.
This study corroborates a note of caution in the inter-
pretation of autoimmune features that are present in
mice with targeted genes located in the telomere region
of chromosome 1. Further studies will be required to
identify the 129- and B6-derived genes whose interaction
leads to the development of SLE.
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Clinical Images: Latency of polyarteritis nodosa until a critical occurrence
The patient, a 53-year-old man, developed upper abdominal pain in February 2004. Laboratory studies for leukocyte, platelet, and
eosinophil counts, C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), antineutrophil cytoplasmic autoantibody,
hepatitis B surface antigen, and hepatitis C antibody yielded normal or negative findings. Three-dimensional computed tomographic
(3-D CT) angiography performed at that time clearly showed multiple aneurysms in the branches of celiac and superior mesenteric
arteries (A). The abdominal pain subsided spontaneously. In February 2007, the patient remained asymptomatic, with an ESR of
5 mm/hour and a CRP level of 0.1 mg/dl. However, 3-D CT angiography (B) revealed new aneurysms in the branches of the same
arteries (arrowheads). He was treated with corticosteroids and intravenous cyclophosphamide, but developed intestinal perforation.
Histologic examination revealed necrotizing arteritis consistent with polyarteritis nodosa.
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